ReviewWorld journal of clinical cases2021
Treatment strategies for hepatocellular carcinoma with extrahepatic metastasis.
Review in World journal of clinical cases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07482670 (Efficacy and Safety of Camrelizumab Plus Rivoceranib and Local Therapy for Hepatocellular Carcinoma With Lung Metastases), which is not on this map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Efficacy and Safety of Camrelizumab Plus Rivoceranib and Local Therapy for Hepatocellular Carcinoma With Lung Metastases (CAPLocal) : A Multicentre, Single-Arm,Prospective Cohort Study
Who cites it
14 citing papers in PubMed, 19 citations in OpenAlex.
- Successful Long-Term Survival With Various Modalities of Treatments Combining Minimally Invasive Surgery for Intrahepatic and Extrahepatic Recurrence of Hepatocellular Carcinoma: A Case Report.Case reports in surgery · 2026Article
- The relationship between resilience, financial toxicity, and quality of life in patients with primary liver cancer: a cross-sectional study.BMC gastroenterology · 2025Article
- Prognostic difference of single metastasis in different sites of hepatocellular carcinoma: a population-based study.Translational cancer research · 2025Article
- MICAL1 Mediates TGF-β1-Induced Epithelial-to-Mesenchymal Transition and Metastasis of Hepatocellular Carcinoma by Activating Smad2/3.Cell biochemistry and biophysics · 2025Article
- Clinical value of systemic immunoinflammatory index in predicting recurrence and metastasis in patients with primary liver cancer.BMC gastroenterology · 2025Article
- Role of transarterial chemoembolization for hepatocellular carcinoma with extrahepatic metastases in the era of advancing systemic therapy.Journal of liver cancer · 2024Article
- Gene Expression Reprogramming by Citrate Supplementation Reduces HepG2 Cell Migration and Invasion.International journal of molecular sciences · 2024Article
- Efficacy of Lenvatinib Combined with PD-1 Inhibitor versus Sorafenib and PD-1 Inhibitor with or Without TACE for Hepatocellular Carcinoma with Extrahepatic Metastasis.ImmunoTargets and therapy · 2024Article
- Dynamics trajectory of patient-reported quality of life and its associated risk factors among hepatocellular carcinoma patients receiving immune checkpoint inhibitors: a prospective cohort study.Frontiers in immunology · 2024Article
- Case report and literature analysis: solitary HCC- recurrence in the right maxillary sinus after curative resection.Frontiers in oncology · 2024Article
- Non-iatrogenic implantation of cutaneous metastasis from hepatocellular carcinoma.Journal of cancer research and clinical oncology · 2023Article
- The Safety and Efficacy of Hepatic Arterial Infusion Chemotherapy Combined with PD-(L)1 Inhibitors and Molecular Targeted Therapies for the Treatment of Intermediate and Advanced Hepatocellular Carcinoma Unsuitable for Transarterial Chemoembolization.Journal of hepatocellular carcinoma · 2023Article
- Therapeutic targeting of alternative splicing to inhibit hepatocellular carcinoma metastasis.Translational cancer research · 2022Article
- Combination approaches in hepatocellular carcinoma: How systemic treatment can benefit candidates to locoregional modalities.World journal of gastroenterology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Extrahepatic metastasis (EHM) of hepatocellular carcinoma (HCC) has increasingly been seen due to improved survival with effective management of intrahepatic lesions. The presence of EHM indicates an advanced stage of HCC, for which systemic therapy serves as the standard treatment modality. Since the approval of Sorafenib as the first systemic agent in 2007, it took almost a decade to show its efficacy in both first and further lines of setting until the landscape of systemic drugs was finally expanded. Moreover, with inspiring results from immunotherapy trials in HCC, it appears that the introduction of immunotherapy may lead to an evolution in the portfolio of HCC treatment. Although the locoregional approach in the management of EHM is not recommended for advanced-stage HCC, efforts have been made to demonstrate its efficacy in symptom relief and potential benefit for overall survival. This review provides a summary of recent updates of the systemic agents in the treatment of advanced HCC, with an emphasis on aggressive locoregional management of EHM by various treatment modalities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.